

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:

C12N 15/19, C07K 14/52, A61K 38/19,
38/48, G01N 33/68

A1

(11) International Publication Number:

WO 99/16876

(43) International Publication Date:

8 April 1999 (08.04.99)

(21) International Application Number: PCT/EP98/06142

(22) International Filing Date: 28 September 1998 (28.09.98)

(30) Priority Data:

97116863.8

97122471.2

98104216.1

29 September 1997 (29.09.97)

19 December 1997 (19.12.97)

10 March 1998 (10.03.98)

EP

EP

EP

(71) Applicant (for all designated States except US): APPLIED
RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL];
John B. Gorsiraweg 14, Curacao (AN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PROOST, Paul [BE/BE];
W. Van den Abeelaan 21, B-3001 Heverlee-Leuven (BE).
STRUYF, Sofie [BE/BE]; Molenstraat 66, B-2841 Rumst
(BE). VAN DAMME, Jo [BE/BE]; Tintorettostraat 32,
B-1000 Brussels (BE).

(74) Agent: PIERACCIOLI, Daniele; Istituto Farmacologico Sero
S.p.a., Via Casilina, 125, I-00176 Rome (IT).

(81) Designated States: AU, BG, BR, CA, CN, CZ, EE, HU, IL,
JP, KP, KR, MX, NO, NZ, PL, SG, SK, UA, US, Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.

(54) Title: AMINO-TERMINALLY TRUNCATED MCP-2 AS CHEMOKINE ANTAGONISTS

(57) Abstract

The present invention relates to amino-terminally truncated MCP-2, lacking NH₂-terminal amino acids corresponding to amino acid residues 1, 1-2, 1-3, 1-4 or 1-5 of the naturally-occurring MCP-2 and having chemokine antagonistic activity, as well as cDNA sequences encoding them, their use in therapy and/or in diagnosis of the diseases, in which an antagonistic activity of the chemokine effects is required, and pharmaceutical compositions comprising them.

PTO
JP 4 57 859



03/28/00